SCHEMBL20211769

SCHEMBL20211769

O=C(O)c1ccc(-c2cn3c(=O)c(Cc4ccco4)nc-3c(Cc3ccccc3)[nH]2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.36
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ ADORA2A P29274 5/20 0.35
▸ ADORA2B P29275 5/20 0.35
▸ MAPT P10636 4/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ HSD17B10 Q99714 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ F2 P00734 1/20 0.35
▸ CSNK2A2 P19784 1/20 0.34
▸ CSNK2A1 P68400 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ TDP1 Q9NUW8 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ USP2 O75604 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ APEX1 P27695 1/20 0.34
▸ CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19810310 0.92 ADORA2B (0.38) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL2670126 0.92 ALDH1A1 (0.39) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL5560844 0.91 ALDH1A1 (0.37) TSHRADORA2AADORA2BKMT2AHSD17B10
SCHEMBL30800214 0.90 KEAP1 (0.39) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL20211740 0.90 KEAP1 (0.39) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL28394541 0.90 ADORA2B (0.35) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL19810320 0.89 LTB4R (0.36) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL28391210 0.89 PRNP (0.36) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL19810212 0.89 ALDH1A1 (0.38) TSHRADORA2AADORA2BMAPTKMT2A
SCHEMBL28888591 0.89 PSD (0.38) TSHRADORA2AADORA2BMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4279490-A2 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2023-11-22 — — EP claimed
US-10577370-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2020-03-03 — — US claimed
EP-3548492-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-10-09 — — EP claimed
WO-2018102693-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-06-07 — — WO claimed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US claimed
EP-4279490-A2 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2023-11-22 — — EP disclosed
EP-3548492-B1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2023-07-05 — — EP disclosed
EP-3548492-B1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORP (US) 2023-07-05 — — EP disclosed
US-11192894-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2021-12-07 — — US disclosed
US-11192894-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2021-12-07 — — US disclosed
US-20200239475-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-07-30 — — US disclosed
US-20200239475-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-07-30 — — US disclosed
US-10577370-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2020-03-03 — — US disclosed
US-10577370-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2020-03-03 — — US disclosed
EP-3548492-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES Promega Corporation (US) 2019-10-09 — — EP disclosed
WO-2018102693-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-06-07 — — WO disclosed
WO-2018102693-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION (US) 2018-06-07 — — WO disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192894-B2 Cell impermeable coelenterazine analogues SI, GLB1, MRPL21 TSHR 4172/4885TAS2R14 3260/4885ADORA2A 2355/4885
US-10577370-B2 Cell impermeable coelenterazine analogues SI, GLB1, MRPL21 TSHR 4172/4885TAS2R14 3260/4885ADORA2A 2355/4885
US-20200239475-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES SI, GLB1, MRPL21 TSHR 4172/4885TAS2R14 3260/4885ADORA2A 2355/4885
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES SI, GLB1, MRPL21 TSHR 4172/4885TAS2R14 3260/4885ADORA2A 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback